4.7 C
London
Sunday, December 5, 2021

Diasorin goes shopping in the US and acquires Luminex

- Advertisement -spot_imgspot_img
- Advertisement -spot_imgspot_img

[ad_1]

DiaSorin – an Italian group listed on the Milan Stock Exchange, with around 2,000 employees and a turnover of 881 million euros – has announced the acquisition of Luminex Corporation for a cash price of $ 37 per share, for a total value of approximately 1 , 8 billion dollars. The agreed price per share represents a premium of about 23.1% compared to the closing price on February 24, 2021 (i.e. the day before rumors about the possible sale of Luminex were leaked) and at a premium of about 30 , 6% and approximately 47.5% of the volume-weighted average price for the 30 and 90-day period prior to February 24, 2021, respectively.

Luminex develops, manufactures and sells proprietary technologies and biological examination products with various applications in the fields of diagnostics and life science. With more than 900 customers, it is an important player in the molecular diagnostics market. Furthermore, Luminex is highly complementary to DiaSorin’s business. The acquisition will strengthen our positioning in the molecular diagnostics market and the current value proposition, in line with the strategic priorities of the group – says DiaSorin in a press release -. Through the acquisition, DiaSorin will gain access to Luminex’s molecular diagnostics technology and multiplexing portfolio, strengthening its offering and expanding its presence in the United States. The acquisition will also allow access to Luminex applications in the life science sector, strengthening DiaSorin’s link with academic and scientific research to anticipate future market trends, creating opportunities for long-term collaboration with biotechnology and pharmaceutical companies ( for example, for the development of vaccines and biologics) and the possibility of developing technology-based tests. Satisfied Group CEO, Carlo Rosa: We are thrilled with this transaction which we believe creates value for our shareholders and represents an exceptional opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostics specialists.

[ad_2]

- Advertisement -spot_imgspot_img
Latest news
- Advertisement -spot_img
Related news
- Advertisement -spot_img

LEAVE A REPLY

Please enter your comment!
Please enter your name here